Tags : BioSticker

BioIntelliSense’s BioSticker Receives FDA’s 510 (k) Clearance for Month-Long Vitals

Tuba Khan February 11, 2020

Shots: BioIntelliSense launches its medical-grade Data-as-a-Service (DaaS) platform and has received 510(k) clearance for BioSticker on-body sensor for scalable remote care in the US The company has developed BioSticker device […]readmore

Tags : BioSticker

BioIntelliSense’s BioSticker Receives FDA’s 510 (k) Clearance for Month-Long Vitals

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : BioSticker

BioIntelliSense’s BioSticker Receives FDA’s 510 (k) Clearance for Month-Long Vitals

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company